Press Releases

Latest Updates

ANNOUNCEMENT: Goodbody Health granted Care Quality Commission registration

Goodbody Health (AQSE: GDBY) is pleased to announce that following its application for registration with the Care Quality Commission (CQC) last year, the Company has successfully passed the registration criteria and now provides all its testing services under the regulated activity diagnostic and screening procedures. CQC is the independent regulator of health and adult social care in England.

ANNOUNCEMENT: AGM, plan to de-list from the CSE, re-domicile to Guernsey and appointment of Peterhouse as Corporate Adviser

Goodbody Health (AQSE: GDBY) today announces its intention to de-list from the Canadian Securities Exchange (“CSE”) and to re-domicile the Company from the Province of British Columbia to Guernsey, subject to shareholder approval. This re-domiciliation is intended to better align Goodbody’s corporate structure with its current and future business activities.

ANNOUNCEMENT: Goodbody Health Inc publishes its 2021 audited Financial Statements

Goodbody Health Inc. is pleased to announce today a positive adjusted EBITDA of £0.48 million in its audited Financial Statements for the year to 31 December 2021. The Company has filed the Financial Statements and Management’s Discussion and Analysis for year ending 2021 with strong results, especially in the second half of the year due to its growth in testing services. All amounts unless stated otherwise are presented in British Pounds (GBP).

ANNOUNCEMENT: Goodbody Health subsidiary granted Home Office controlled drugs licence

Goodbody Health (AQSE: GDBY) is pleased to announce that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs. This comes as the UK authorities look to the regulation of the UK consumer cannabinoid product testing infrastructure ahead of wider compliance within the industry.

ANNOUNCEMENT: Goodbody Health products included on FSA Novel Foods Register

Goodbody Health (AQSE: GDBY) is pleased to announce that, following the UK Food Standard Agencies (FSA) publication of the Novel Foods approved list for CBD, the Company’s application has been authorised by the FSA to the next stage of the Novel Foods submission, being the publication of the Awaiting Evidence List. This means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress onto the final Validated list.